EUROLAB
ich-e14-qt-interval-evaluation-and-impurity-impact
Impurity Profiling EMA Guideline on Genotoxic Impurities in PharmaceuticalsEMA Reflection Paper on Low Level ImpuritiesFDA Guidance: Microbial Impurities and Endotoxin LevelsFDA Guidance: Threshold of Toxicological Concern (TTC) for ImpuritiesFDA ICH M3(R2): Impurities in Safety StudiesFDA Q&A on Impurities in Generic Drug ApplicationsFDA Q&A: Managing Impurities in Complex APIsICH M7: Mutagenic Impurity Risk AssessmentICH Q10: Pharmaceutical Quality System for Impurity ManagementICH Q11: Impurity Control Strategy in Drug Substance DevelopmentICH Q12: Lifecycle Management of Impurity Control StrategyICH Q1E: Evaluation of Stability Data Related to Impurity FormationICH Q2(R1): Validation of Analytical Methods for Impurity TestingICH Q3A: Organic Impurity Profiling in Drug SubstancesICH Q3B: Impurity Testing in Finished Drug ProductsICH Q3C: Residual Solvent ProfilingICH Q3D: Elemental Impurity Risk AssessmentICH Q3F: Impurity Guidelines for Biotechnology ProductsICH Q4B: Harmonization of Analytical Procedures for Impurity TestingICH Q5C: Impurity Monitoring in Biotechnological ProductsICH Q6A: Specifications and Acceptance Criteria for ImpuritiesICH S3A: Impurities Arising from Degradation ProductsICH S6: Biotech Product Impurity ProfilingICH S7A: Safety Pharmacology Impurity EvaluationICH S9: Impurities in Oncology ProductsISO 10993-18: Chemical Characterization and Impurity AnalysisISO 17025: Accreditation for Impurity Testing LaboratoriesJP General Rule 2.60: Limit Test for ImpuritiesPh. Eur. 2.2.28: Gas Chromatography for Impurity DetectionPh. Eur. 2.2.38: Thin-Layer Chromatography for ImpuritiesPh. Eur. 2.2.46: Chromatographic Separation for Impurity AnalysisPh. Eur. 2.4.14: Determination of Inorganic ImpuritiesPh. Eur. 2.4.20: Limit Test for Heavy Metals in ImpuritiesPh. Eur. 2.4.24: Related Substances by HPLC in APIsPh. Eur. 2.4.29: Limit Test for Sulfated Ash ImpuritiesPh. Eur. 2.5.13: Oxidizing Impurity TestsPh. Eur. 2.9.40: Uniformity of Dosage Units and Related ImpuritiesPh. Eur. 5.10: Control of Impurities in Substances for Pharmaceutical UsePh. Eur. 5.4: Impurities in Radiopharmaceutical PreparationsUSP <1010>: Analytical Data Integrity in Impurity ReportingUSP <1031>: The Biocompatibility of Materials and ImpuritiesUSP <1051>: Cleaning Validation Limits and Residual ImpuritiesUSP <1058>: Analytical Instrument Qualification for Impurity StudiesUSP <1078>: Good Manufacturing Practices for Impurity ReductionUSP <1085>: Evaluation of Impurity Method PerformanceUSP <1086>: Impurities in Drug SubstancesUSP <1088>: Forced Degradation Studies for Impurity CharacterizationUSP <1091>: Impurity Isolation and Characterization TechniquesUSP <1099>: Acceptable Analytical Performance CriteriaUSP <1121>: Bulk Pharmaceutical Chemicals and Impurity HandlingUSP <1151>: Pharmaceutical Dosage Forms and Impurity ConsiderationUSP <1191>: Stability Testing of Compounded PreparationsUSP <1222>: Terminal Sterilization Impact on ImpuritiesUSP <1224>: Transfer of Impurity Test ProceduresUSP <1225>: Validation of Compendial Procedures for ImpuritiesUSP <1226>: Verification of Compendial Procedures for Impurity DetectionUSP <1231>: Water for Pharmaceutical Purposes and Impurity EffectsUSP <1232>: Water Activity and Impurity StabilityUSP <1241>: Capsules and Shell Impurity InteractionUSP <1251>: Weighing on Analytical Balances for Micro-ImpuritiesUSP <161>: Transdermal Delivery Systems and Impurity ControlUSP <197>: Spectrophotometric Identification of ImpuritiesUSP <233>: Elemental Impurities Profiling Using ICP-MSUSP <41>: Balances Used for Impurity Weight DeterminationUSP <466>: Identification and Quantification of DegradantsUSP <467>: Residual Solvent Testing in APIs and ExcipientsUSP <476>: Impurity Profiling for New Drug ApplicationsUSP <621>: Chromatography Conditions for Impurity IdentificationUSP <730>: Plasma Spectrochemistry for Impurity ProfilingUSP <791>: pH Determination Impact on Impurity SolubilityUSP <797>: Sterile Compounding and Impurity ControlUSP <800>: Hazardous Drug Handling Based on Impurity RiskUSP <851>: Spectrophotometry and Light Scattering for ImpuritiesUSP <853>: Atomic Absorption Spectroscopy for Trace ImpuritiesUSP <857>: UV-Vis Spectroscopy for Impurity QuantificationUSP <85>: Bacterial Endotoxin Limits Related to Impurity SafetyUSP <891>: Nuclear Magnetic Resonance (NMR) for Structural ElucidationUSP <905>: Content Uniformity Related to ImpuritiesUSP <905>: Uniformity of Dosage Units Affected by ImpuritiesUSP <941>: Characterization of Impurity Solubility and pKaWHO TRS 970 Annex 2: Impurity Control in Medicines

Comprehensive Guide to ICH E14: QT Interval Evaluation and Impurity Impact Testing Services

Provided by Eurolab

ICH E14: QT Interval Evaluation and Impurity Impact testing is a critical laboratory test that ensures the safety of pharmaceuticals and other medicinal products. This test is governed by various international and national standards, including ISO, ASTM, EN, TSE, and others.

Legal and Regulatory Framework

The legal and regulatory framework surrounding ICH E14: QT Interval Evaluation and Impurity Impact testing is complex and multifaceted. The International Conference on Harmonisation (ICH) guidelines are the primary reference for this test. ICH E14 provides a comprehensive framework for evaluating the QT interval prolongation potential of pharmaceuticals.

International and National Standards

The following international and national standards apply to ICH E14: QT Interval Evaluation and Impurity Impact testing:

  • ISO 10993-1:2018 Biological evaluation of medical devices Part 1: Evaluation and testing

  • ASTM E2110-18 Standard guide for the estimation of acute toxicity from a single oral dose in rats

  • EN ISO 10993-17:2012 Biological evaluation of medical devices -- Part 17: Tests for cytotoxicity: In vitro methods

  • TSE (Turkish Standards Institution) TS 12125:2016 Biological evaluation of medical devices Part 1: Evaluation and testing

    • Standard Development Organizations

    The following standard development organizations play a crucial role in the development and maintenance of standards related to ICH E14: QT Interval Evaluation and Impurity Impact testing:

  • International Organization for Standardization (ISO)

  • American Society for Testing and Materials (ASTM)

  • European Committee for Standardization (CEN)

    • Evolution of Standards

    Standards evolve over time to reflect changes in technology, scientific understanding, and regulatory requirements. The following examples illustrate how standards can change:

  • ISO 10993-1:2018 supersedes the previous edition (ISO 10993-1:2009)

  • ASTM E2110-18 supersedes the previous edition (ASTM E2110-05)

    • Compliance Requirements

    Pharmaceutical companies must comply with various industry-specific standards to ensure that their products meet regulatory requirements. The following examples illustrate compliance requirements for different industries:

  • Pharmaceutical: ICH E14 guidelines

  • Medical Device: ISO 10993-1:2018 and EN ISO 10993-17:2012

    • Standard Numbers and Scope

    The following standard numbers and scope provide a comprehensive overview of the standards related to ICH E14: QT Interval Evaluation and Impurity Impact testing:

    Standard Number Title

    --- ---

    ISO 10993-1:2018 Biological evaluation of medical devices Part 1: Evaluation and testing

    ASTM E2110-18 Standard guide for the estimation of acute toxicity from a single oral dose in rats

    EN ISO 10993-17:2012 Biological evaluation of medical devices -- Part 17: Tests for cytotoxicity: In vitro methods

    Why This Test is Needed and Required

    ICH E14: QT Interval Evaluation and Impurity Impact testing is essential to ensure the safety of pharmaceuticals and other medicinal products. The consequences of not performing this test can be severe, including:

  • Regulatory non-compliance

  • Product recalls

  • Financial losses

    • Business and Technical Reasons for Conducting ICH E14: QT Interval Evaluation and Impurity Impact Testing

    Conducting ICH E14: QT Interval Evaluation and Impurity Impact testing provides several business and technical benefits, including:

  • Quality assurance and compliance with regulatory requirements

  • Enhanced product safety and reliability

  • Competitive advantages through innovation and research development support

    • Industries and Sectors that Require This Testing

    The following industries and sectors require ICH E14: QT Interval Evaluation and Impurity Impact testing:

  • Pharmaceutical

  • Medical Device

  • Cosmetics

    • Risk Factors and Safety Implications

    ICH E14: QT Interval Evaluation and Impurity Impact testing helps to identify potential risks and safety implications associated with pharmaceuticals and other medicinal products. This includes:

  • Cardiac arrhythmias and conduction disorders

  • Cytotoxicity and genotoxicity

  • Immunogenicity and hypersensitivity

    • Quality Assurance and Quality Control

    ICH E14: QT Interval Evaluation and Impurity Impact testing is subject to quality assurance and quality control measures, including:

  • Calibration and validation of equipment and instruments

  • Sample preparation and storage procedures

  • Data collection and recording procedures

    • Contribution to Product Safety and Reliability

    ICH E14: QT Interval Evaluation and Impurity Impact testing contributes significantly to product safety and reliability by:

  • Identifying potential risks and safety implications

  • Enhancing quality assurance and compliance with regulatory requirements

  • Providing competitive advantages through innovation and research development support

    • Competitive Advantages of Having This Testing Done

    Conducting ICH E14: QT Interval Evaluation and Impurity Impact testing provides several competitive advantages, including:

  • Enhanced product safety and reliability

  • Compliance with regulatory requirements

  • Innovation and research development support

    • Why Choose Eurolab for ICH E14: QT Interval Evaluation and Impurity Impact Testing?

    Eurolab is a leading laboratory service provider that offers comprehensive ICH E14: QT Interval Evaluation and Impurity Impact testing services. Our experienced team of professionals ensures that your products meet the highest standards of quality, safety, and compliance.

    Conclusion

    ICH E14: QT Interval Evaluation and Impurity Impact testing is a critical laboratory test that ensures the safety of pharmaceuticals and other medicinal products. This comprehensive guide provides an overview of the standard-related information, legal and regulatory framework, international and national standards, standard development organizations, evolution of standards, compliance requirements, standard numbers and scope, why this test is needed and required, business and technical reasons for conducting ICH E14: QT Interval Evaluation and Impurity Impact testing, industries and sectors that require this testing, risk factors and safety implications, quality assurance and quality control, contribution to product safety and reliability, competitive advantages of having this testing done, and why choose Eurolab for ICH E14: QT Interval Evaluation and Impurity Impact testing.

    Need help or have a question?
    Contact us for prompt assistance and solutions.

    CONTACT US +902127020000

    Latest News

    View all

    Eurolab Successfully Renews ISO 17025 Accreditation

    Read More

    Expanded Cosmetic Safety Testing Portfolio Now Available at Eurolab

    Read More

    Eurolab Launches Technical Training Series for Industry Professionals

    Read More

    JOIN US
    Want to make a difference?

    Careers